Tranexamic acid

Chemical formula: C₈H₁₅NO₂  Molecular mass: 157.21 g/mol  PubChem compound: 5526

Therapeutic indications

Tranexamic acid is indicated for:

Local fibrinolysis in menorrhagia

Population group: women, only adults (18 - 65 years old)

Disorder of fibrinolysis and additionally Menorrhagia

For this indication, competent medicine agencies globally authorize below treatments (click for details):

Prevention of haemorrhages due to general or local fibrinolysis

Population group: only children (1 year - 12 years old) , adolescents (12 years - 18 years old) , adults (18 years old or older)

Prevention of haemorrhages due to general or local fibrinolysis in adults and children from one year.

Specific indications include:

  • Haemorrhage caused by general or local fibrinolysis such as:
    • Menorrhagia and metrorrhagia,
    • Gastrointestinal bleeding,
    • Haemorrhagic urinary disorders, further to prostate surgery or surgical procedures affecting the urinary tract.

For this indication, competent medicine agencies globally authorize below treatments (click for details):

Risk of haemorrhage in increased fibrinolysis or fibrinogenolysis

Population group: only children (1 year - 12 years old) , adolescents (12 years - 18 years old) , adults (18 years old or older)

at least one of
Disorder of fibrinolysis and additionally Bleeding

Increased fibrinolysis
Disseminated intravascular coagulation

For this indication, competent medicine agencies globally authorize below treatments (click for details):

Management of haemorrhage due to the administration of a fibrinolytic agent

Population group: only children (1 year - 12 years old) , adolescents (12 years - 18 years old) , adults (18 years old or older)

Antithrombotic agents and additionally Bleeding

For this indication, competent medicine agencies globally authorize below treatments (click for details):

Haemorrhage in increased fibrinolysis or fibrinogenolysis

Population group: only children (1 year - 12 years old) , adolescents (12 years - 18 years old) , adults (18 years old or older)

Short-term use for haemorrhage or in increased fibrinolysis or fibrinogenolysis.

For this indication, competent medicine agencies globally authorize below treatments (click for details):

Local fibrinolysis in metrorrhagia

Population group: women, only adults (18 - 65 years old)

Disorder of fibrinolysis and additionally Metrorrhagia

For this indication, competent medicine agencies globally authorize below treatments (click for details):

Local fibrinolysis in epistaxis

Population group: only adults (18 years old or older)

Disorder of fibrinolysis and additionally Bleeding from nose

For this indication, competent medicine agencies globally authorize below treatments (click for details):

Local fibrinolysis in conisation of the cervix

Population group: women, only adults (18 years old or older)

Disorder of fibrinolysis and additionally Cone biopsy of cervix

For this indication, competent medicine agencies globally authorize below treatments (click for details):

Local fibrinolysis in traumatic hyphaema

Population group: only adults (18 years old or older)

Disorder of fibrinolysis and additionally Traumatic hyphaema

For this indication, competent medicine agencies globally authorize below treatments (click for details):

Local fibrinolysis in hereditary angioneurotic edema

Population group: only adults (18 years old or older)

Disorder of fibrinolysis and additionally Hereditary angioneurotic edema

For this indication, competent medicine agencies globally authorize below treatments (click for details):

Management of dental extraction in haemophiliacs

Population group: only adults (18 years old or older)

Disorder of fibrinolysis and additionally
Tooth extraction and additionally Hemophilia

For this indication, competent medicine agencies globally authorize below treatments (click for details):

Haemorrhages due to general or local fibrinolysis

Population group: only children (1 year - 12 years old) , adolescents (12 years - 18 years old) , adults (18 years old or older)

Treatment of haemorrhages due to general or local fibrinolysis in adults and children from one year.

Specific indications include:

  • Haemorrhage caused by general or general or local fibrinolysis such as:
    • Menorrhagia and metrorrhagia,
    • Gastrointestinal bleeding,
    • Haemorrhagic urinary disorders, further to prostate surgery or surgical procedures affecting the urinary tract.

For this indication, competent medicine agencies globally authorize below treatments (click for details):

Fibrinolysis in ear, nose and throat surgery

Population group: only children (1 year - 12 years old) , adolescents (12 years - 18 years old) , adults (18 years old or older)

Ear, nose and throat surgery (adenoidectomy, tonsillectomy, dental extractions).

For this indication, competent medicine agencies globally authorize below treatments (click for details):

Fibrinolysis in gynaecological surgery or disorders of obstetric origin

Population group: women, only children (1 year - 12 years old) , adolescents (12 years - 18 years old) , adults (18 years old or older)

Disorder of fibrinolysis and additionally at least one of
Procedure on female genital system
Complication of pregnancy, childbirth and/or puerperium

For this indication, competent medicine agencies globally authorize below treatments (click for details):

Fibrinolysis in major surgical intervention

Population group: only children (1 year - 12 years old) , adolescents (12 years - 18 years old) , adults (18 years old or older)

Thoracic and abdominal surgery and other major surgical intervention such as cardiovascular surgery.

For this indication, competent medicine agencies globally authorize below treatments (click for details):

Contraindications

Tranexamic acid is contraindicated in the following cases:

History of venous or arterial thrombosis

at least one of
Thrombosis
H/O: thrombosis

Fibrinolytic conditions following consumption coagulopathy

Fibrinolytic bleeding syndrome

Severe renal impairment

at least one of

Renal failure stage 5: Kidney failure (GFR <15 mL/min/1.73 m2 or dialysis)

History of convulsions

at least one of
Seizure
History of seizure

Active thromboembolic disease

Thromboembolic disorder

Subarachnoid haemorrhage

Subarachnoid hemorrhage

Get recommendations

Factors such as age, gender, and health history are evaluated to create a personalized medication regimen.

Ask the Reasoner

Related medicines

Summary of Product Characteristics (SPC) 2016: AZEPTIL Solution for injection
Structured Product Labeling (SPL/PLR) 2021: CYKLOKAPRON Solution for injection
Summary of Product Characteristics (SPC) 2023: AZEPTIL Capsule, hard
< Previous: Overview
Next: Precautions >

© All content on this website, including data entry, data processing, decision support tools, "RxReasoner" logo and graphics, is the intellectual property of RxReasoner and is protected by copyright laws. Unauthorized reproduction or distribution of any part of this content without explicit written permission from RxReasoner is strictly prohibited. Any third-party content used on this site is acknowledged and utilized under fair use principles.

⇈